Chasnay Capital invests in Sleep Cogni after successful clinical trial

Chasnay Capital Investments has invested in UK-designed sleep therapy solution, SleepCogni. This funding follows SleepCogni’s recent successful clinical trial which showed they could significantly reduce clinical insomnia in seven days. 

SleepCogni provides insomnia sufferers with a handheld sleeping aid which breaks cognitive cycles that prevent sleep using patented technology. A feature of SleepCogni as a medical device is that it helps users self-manage their insomnia providing a true solution for this condition that severely impacts on wellbeing and overall health. Cornerstone investors, Chasnay, will bring in a wealth of knowledge with their understanding of the healthcare market. 

SleepCogni recently registered with the Food and Drug Administration (FDA). There are an estimated 70 million sleep sufferers living in the US, and FDA registration will allow SleepCogni to sell into this market directly. On a global level the sleep aid market is valued at 

$80 billion. SleepCogni’s recent progress with key results from their first clinical trial and with sleep clinics lined up to roll out our product and participate in further trials, make it ideally positioned to become a key leader in this large and global market.

SleepCogni founder and CEO, Richard Mills, added: “This investment from Chasnay Capital Investments truly shows the size of the opportunity and our global ambition. The three former GE executives are proven titans in the healthcare industry and with their combined 80 years’ experience they will aid and advise on our international expansion and global rollout.”  

Reinaldo Garcia from Chasnay Capital Investments added: “We invest in companies with ambition for global success where we can add value. As experienced global senior leaders with a proven track record we help companies improve strategy, team and build scale and help them transform into global businesses.

“We are very excited by our investment into SleepCogni; the patented technology, the size of the unmet need in the global sleep space, and the opportunity to become a global leader with a clinically validated solution all positioned perfectly for where we can add value in this next exciting stage of the business. We also really liked the team, led by chairman, Richard di Benedetto and CEO, Richard Mills backed with a solid scientific team led by CSO, Dr Maan van de Werken.”